Study of XL999 in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring Colon Cancer
Eligibility Criteria
Inclusion Criteria: Males and females with histologically confirmed metastatic colorectal cancer Measurable disease according to Response Criteria for Solid Tumors (RECIST) At least 1 prior therapeutic regimen (chemotherapy or biologic) ECOG performance status of 0 or 1 Life expectancy ≥3 months Adequate organ and marrow function No other malignancies within 5 years Signed informed consent Exclusion Criteria: Radiation to ≥25% of bone marrow within 30 days of XL999 treatment Treatment with systemic anticancer therapy within 30 days of XL999 treatment Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered >30 days prior to study enrollment History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis Uncontrolled and/or intercurrent illness Pregnant or breastfeeding females Known HIV
Sites / Locations
- California Cancer Care, Inc.
- Integrated Community Oncology Network; Division of Clinical Research
- Hematology Oncology Associated of the Treasure Coast
- University of Chicago
- Joliet Oncology-Hematology Associated, Ltd.
- Indiana University Cancer Center
- Hematology Oncology Associates of Rockland, PC
- Center for Oncology Research and Treatment, PA